BiomX Inc. (NYSEAMERICAN:PHGE) Sees Large Drop in Short Interest

BiomX Inc. (NYSEAMERICAN:PHGE) saw a significant drop in short interest in July. As of July 15th, there was short interest totaling 190,323 shares, a drop of 79.5% from the June 30th total of 929,023 shares. Approximately 1.6% of the shares of the company are short sold. Based on an average trading volume of 8,831,855 shares, the days-to-cover ratio is currently 0.0 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in BiomX stock. Citadel Advisors LLC bought a new stake in shares of BiomX Inc. (NYSEAMERICAN:PHGE) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned approximately 0.61% of BiomX at the end of the most recent reporting period. Institutional investors own 40.57% of the company’s stock.

BiomX Price Performance

NYSEAMERICAN:PHGE opened at $0.19 on Friday. The company has a 50 day moving average price of $0.55 and a 200-day moving average price of $2.61. BiomX has a 1-year low of $0.18 and a 1-year high of $13.70. The firm has a market cap of $2.23 million, a price-to-earnings ratio of -0.06 and a beta of 1.30.

BiomX (NYSEAMERICAN:PHGE) last released its quarterly earnings data on Wednesday, May 20th. The company reported $7.38 earnings per share for the quarter. On average, sell-side analysts anticipate that BiomX will post -5.85 earnings per share for the current fiscal year.

BiomX Company Profile

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.